Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Equillium, Inc.EQ · Entity 6560 | Director | May 28, 2026 | May 29, 2026 |
| Neurogene Inc.AQXP · Entity 5160 | Chief Medical Officer | March 09, 2018 | March 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Equillium, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2036-05-27 | Direct | 70,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 70,000 · Balance 70,000 F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date.
Neurogene Inc.
Report date March 09, 2018 · Filed March 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.55 · Expires 2028-03-08 | Direct | 75,000 |
Reported balance
After 2018-03-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-03-09 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of March 9, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of March 9, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 22:10 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001627886-26-000001 · form4-05292026_100513.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 28, 2026, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 21, 2025 Filed May 23, 2025 17:41 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001415889-25-014396 · form4-05232025_050527.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-05-20 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 21, 2025, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:30 UTC | Equillium, Inc. EQ · Entity 6560 | Disposition to issuerDirector Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $3.59 | Not disclosed |
DisclosureSEC source: 0001415889-25-004754 · form4-02202025_120257.xml · derivative · entry 2 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2032-02-29 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: The option vests in 36 equal monthly installments following the grant date of March 1, 2022. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 00:30 UTC | Equillium, Inc. EQ · Entity 6560 | GrantDirector Stock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $0.79 | Not disclosed |
DisclosureSEC source: 0001415889-25-004754 · form4-02202025_120257.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-29 F2 · price: On August 7, 2023, the Board of Directors of the Company approved the repricing of certain options based on the closing price of the Company's common stock on August 14, 2023. The repricing of these options was subject to a holding period that lapsed on February 14, 2025. The repricing resulted in the impacted options having a lower exercise price of $0.785 per share, which is the closing price of the Company's common stock on the Nasdaq Capital Market on August 14, 2023. All of the other terms of the options remained unchanged. F1 · derivative.exercise_date: The option vests in 36 equal monthly installments following the grant date of March 1, 2022. Read SEC document |
| May 22, 2024 Filed May 23, 2024 21:54 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.43 | $0.00 |
DisclosureSEC source: 0001415889-24-014358 · form4-05232024_090501.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2024, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| May 22, 2023 Filed May 23, 2023 22:12 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001209191-23-031720 · doc4.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-05-22 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments commencing on the grant date of May 22, 2023, provided that the option will, in any case, be fully vested on the date of the Issuer's annual meeting of stockholders following the grant date. Read SEC document |
| March 01, 2022 Filed Mar 8, 2022 22:46 UTC | Equillium, Inc. EQ · Entity 6560 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001209191-22-017194 · doc4.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-29 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments following the grant date of March 1, 2022. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:04 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0001209191-18-019267 · doc4.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-03-08 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of March 9, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| March 08, 2017 Filed Mar 11, 2017 02:22 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.35 | $0.00 |
DisclosureSEC source: 0001209191-17-020014 · doc4.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-03-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of March 8, 2017 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date. Read SEC document |
| November 08, 2016 Filed Nov 10, 2016 22:38 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0001209191-16-149432 · doc4.xml · derivative · entry 1 Troupin Barbara · CIK 0001627886 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-11-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of October 3, 2016 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.